A US drug-agency clampdown is unwarranted without evidence of harm, say Robert C. Green and Nita A. Farahany.
This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Carver, K. H. Food Drug Law J. 63, 151–215 (2008).
Kalf, R. R. J. et al. Genet. Med. http://dx.doi.org/10.1038/gim.2013.80 (2013).
Swan, M. Genet. Med. 12, 279–288 (2010).
Bloss, C. S. et al. Genet. Med. 12, 556–566 (2010).
Bloss, C. S., Schork, N. J. & Topol, E. J. N. Engl. J. Med. 364, 524–534 (2011).
Green, R. C. et al. N. Engl. J. Med. 361, 245–254 (2009).
Lautenbach, D. M., Christensen, K. D., Sparks, J. A. & Green, R. C. Annu. Rev. Genomics Hum. Genet. 14, 491–513 (2013).
Kaufman, D. J., Bollinger, J. M., Dvoskin, R. L. & Scott, J. A. J. Genet. Couns. 21, 413–422 (2012).
Francke, U. et al. PeerJ 1, e8 (2013).
Topol, E. The Creative Destruction of Medicine (Basic, 2012).
R.C.G. leads several NIH research projects on genetic disclosure including one completed project, the Impact of Personal Genomics or PGen Study, (R01-HG005092) Scientists from two companies, 23andMe and Pathway Genomics interact with this study but have no control over data, analysis or publications. R.C.G. has, without compensation, contributed self-scripted, non-exclusive educational material to the 23andMe website. R.C.G. has not received personal financial support from any of the above entities; he has received support from the Brin-Wojcicki Foundation for an unrelated sequencing project.
Related links in Nature Research
Related external links
Nature’s Kerri Smith looks at the recent FDA crackdown on 23andMe
About this article
Cite this article
Green, R., Farahany, N. Regulation: The FDA is overcautious on consumer genomics. Nature 505, 286–287 (2014). https://doi.org/10.1038/505286a
This article is cited by
Medicine, Health Care and Philosophy (2023)
Direct-to-Consumer Genetic Testing and Its Marketing: Emergent Ethical and Public Policy Implications
Journal of Business Ethics (2022)
Cardiovascular Drugs and Therapy (2021)
European Journal of Human Genetics (2018)
BMC Medical Genomics (2017)